Market Movers (8-K)
See all →Iris Acquisition Corp. stockholders overwhelmingly approved the business combination with Liminatus Pharma at a special meeting held on March 4, 2025.
Iris Acquisition Corp has filed an amendment to its registration statement related to its proposed business combination with Liminatus Pharma.
Iris Acquisition Corp has filed an amendment to its registration statement regarding its proposed business combination with Liminatus Pharma, moving closer to a shareholder vote.
Iris Acquisition Corp. determined that previously issued financial statements for Q2 and Q3 2024 should no longer be relied upon due to an undisclosed related party loan.
Worse than expected
Iris Acquisition Corp. has extended the deadline for its business combination with Liminatus Pharma to June 30, 2025, after securing shareholder approval and amending related agreements.
Worse than expected
Delay expected
Iris Acquisition Corp reports a $1.12 million loan facilitated by an affiliate of Liminatus Pharma's CEO to enable the acquisition of the former managing member of the company's sponsor.
Delay expected
Quarterly Earnings (10-Q)
See all →10-Q/A: Iris Acquisition Corp Restates Financials Due to Related Party Transaction and Material Weakness
Iris Acquisition Corp restated its financials for the period ended September 30, 2024, due to an undisclosed related party transaction and the identification of a material weakness in internal control over financial reporting.
Worse than expected
Delay expected
Capital raise
10-Q/A: Iris Acquisition Corp Restates Financials Due to Related Party Transaction and Material Weakness
Iris Acquisition Corp files an amended 10-Q/A to restate its financials for the period ended June 30, 2024, due to an undisclosed related party transaction and the identification of a material weakness in internal control over financial reporting.
Worse than expected
Delay expected
Capital raise
10-Q: Iris Acquisition Corp Reports Q3 2024 Results Amidst Business Combination Extension and Delisting
Iris Acquisition Corp's Q3 2024 report reveals a net loss, ongoing business combination efforts, and a delisting from Nasdaq, with trading now on the OTC Pink Marketplace.
Worse than expected
Delay expected
Capital raise
Iris Acquisition Corp reported a net loss for the second quarter of 2024 and is facing challenges in completing its business combination with Liminatus Pharma.
Worse than expected
Delay expected
Capital raise
Iris Acquisition Corp reported a net loss of $858,231 for the quarter ended March 31, 2024, as it continues to pursue a business combination with Liminatus Pharma.
Worse than expected
Delay expected
Capital raise
Iris Acquisition Corp reported a net loss of $323,891 for the third quarter of 2023, as it continues to pursue a business combination with Liminatus Pharma.
Worse than expected
Delay expected
Capital raise
Annual Reports (10-K)
Iris Acquisition Corp's 10-K filing reveals challenges in completing a business combination by June 30, 2025, alongside material weaknesses in internal controls.
Delay expected
Capital raise
Worse than expected
10-K: Iris Acquisition Corp Amends Business Combination Agreement, Extends Deadline to July 31, 2024
Iris Acquisition Corp extends the deadline for its business combination with Liminatus Pharma to July 31, 2024, through a third amendment to their agreement.
Delay expected
Worse than expected
Insider Trading (Form 4)
See all →Iris Acquisition Corp has filed an amendment to its registration statement related to the proposed business combination with Liminatus Pharma.
Iris Acquisition Corp has filed an amendment to its registration statement related to its proposed business combination with Liminatus Pharma.
Iris Acquisition Corp has filed an amendment to its registration statement related to the proposed business combination with Liminatus Pharma.
Iris Acquisition Corp. and Liminatus Pharma have amended their business combination agreement for the sixth time, significantly reducing the enterprise value of Liminatus to $175 million.
Worse than expected
Delay expected
Capital raise
Iris Acquisition Corp has filed an amendment to its registration statement related to the proposed business combination with Liminatus Pharma.
Iris Acquisition Corp has filed an amendment to its registration statement related to the proposed business combination with Liminatus Pharma.
Proxy Statements (Def-14A)
Iris Acquisition Corp is asking stockholders to approve a business combination with Liminatus Pharma, involving a merger and stock issuance, at a special meeting on March 4, 2025.
Worse than expected
Delay expected
Capital raise
Iris Acquisition Corp discloses a late notification regarding a loan provided to facilitate the acquisition of its sponsor's former managing member.
Worse than expected
Delay expected
Iris Acquisition Corp is seeking stockholder approval to extend the deadline for completing a business combination to March 31, 2025, with a potential further three-month extension, and has scheduled a special meeting for December 20, 2024, to vote on the matter.
Worse than expected
Delay expected
Iris Acquisition Corp is seeking stockholder approval to extend the deadline for completing a business combination to December 31, 2024, due to recent challenges with its proposed merger with Liminatus Pharma.
Worse than expected
Delay expected
Iris Acquisition Corp. is asking its stockholders to approve a business combination with Liminatus Pharma, a clinical-stage biopharmaceutical company.
Delay expected
Capital raise